Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
Harrow Health, Inc. HROW
$30.48 -0.42% Close, Oct 2, 2026 · NASDAQ · Market cap $1.14B
Weak trend
Next earnings report: Nov 9, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Net debt is 48.4× EBITDA, a high level of leverage.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
- Revenue over the last four quarters was $275.6M, up 21.1% from a year earlier, slowing from 26.2% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth69Positive
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 31%
- Revenue growth, 3-year CAGRTop 15%
- Revenue growth accelerationBottom 25%
Quality66Positive
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 29%
- Gross marginTop 38%
- Operating marginTop 39%
- Accruals (lower is better)Top 33%
- Net debt / EBITDA (lower is better)Bottom 1%
- Interest coverTop 43%
Value65Positive
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 39%
- Free-cash-flow yieldTop 34%
- EBITDA / enterprise valueTop 37%
- Sales / enterprise valueBottom 48%
Momentum17Very weak
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 23%
- 6-month returnBottom 28%
- 1-year return vs S&P 500Bottom 17%
- Distance from 52-week highBottom 35%
- Trend checklist (0–4)Bottom 14%
Revisions42Weak
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 11%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 33%
Stability32Weak
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 27%
- Maximum drawdown, 3 yearsTop 37%
- Beta vs S&P 500 (lower is better)Bottom 10%
- Net debt / EBITDA (lower is better)Bottom 1%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 26.2% | 21.1% | ↓ |
| Gross margin | 74.6% | 73.3% | ↓ |
| Operating margin | 6.3% | 2.1% | ↓ |
| FCF margin | -15.2% | 2.1% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 21.1% | 26.2% | ↓ | Top 31% |
| Gross margin | 73.3% | 74.6% | ↓ | Top 38% |
| Operating margin | 2.1% | 6.3% | ↓ | Top 39% |
| Net margin | -13.5% | -4.5% | ↓ | — |
| Free-cash-flow margin | 2.1% | -15.2% | ↑ | — |
| Return on invested capital | 1.8% | — | Top 29% | |
| Revenue growth, 3-year CAGR | 45.4% | — | Top 15% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -10.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 2.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +29.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 48.37×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 0.2×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.03%
- Shareholder yield
- -0.03%
- Share count change, 1 year
- -3.9%
- Share count change, 3-year CAGR
- +7.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 10, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -92.7%
- Average 2-day reaction, last 8
- -0.2%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $66.50
- Target vs current price
- +118.2%
- Analysts with a rating
- 10
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 10, 2026 | -157.3% | +0.6% | -1.0% | -4.7% | — |
| May 11, 2026 | -72.1% | -0.5% | -18.4% | -13.4% | +3.1% |
| Mar 2, 2026 | -55.0% | -1.1% | -32.9% | -37.6% | -36.9% |
| Nov 10, 2025 | -86.4% | +0.6% | +20.2% | +39.9% | +35.8% |
| Aug 11, 2025 | +1754.3% | -2.0% | +12.8% | +15.5% | +4.4% |
| May 8, 2025 | -2600.0% | -4.1% | +2.2% | +16.8% | +35.9% |
| Mar 27, 2025 | +192.7% | +0.8% | -5.8% | -9.3% | +12.1% |
| Nov 13, 2024 | -140.0% | +3.8% | -20.5% | -24.4% | -36.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.46 | -$0.18 | -157.3% | $70.7M |
| May 11, 2026 | -$0.74 | -$0.43 | -72.1% | $44.2M |
| Mar 2, 2026 | $0.18 | $0.40 | -55.0% | $89.1M |
| Nov 10, 2025 | $0.03 | $0.22 | -86.4% | $71.6M |
| Aug 11, 2025 | $0.14 | $0.01 | +1754.3% | $63.7M |
| May 8, 2025 | -$0.50 | $0.02 | -2600.0% | $47.8M |
| Mar 27, 2025 | $0.24 | $0.08 | +192.7% | $66.8M |
| Nov 13, 2024 | -$0.12 | -$0.05 | -140.0% | $49.3M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / EBITDA | 301.8× | — | — | Top 37% |
| EV / Sales | 4.91× | — | — | Bottom 48% |
| Free-cash-flow yield | 0.50% | — | — | Top 34% |
| Earnings yield | -3.26% | — | — | Top 39% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -9.2%
- 200-day average slope (20 days)
- -2.3%
- Distance from 50-day average
- -17.9%
- Distance from 200-day average
- -24.5%
- RSI (14)
- 26.1
- Relative volume
- 0.98×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 43.5%
- Volatility vs own 5-year history
- 4th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.14
- Correlation with S&P 500
- 0.48
- Current drawdown from 1-year high
- -44.4%
- Maximum drawdown, 3 years
- -61.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| May 9, 2023 | Nov 15, 2023 | -71.2% | 132 days | 182 days (Aug 8, 2024) |
| Oct 18, 2024 | Apr 8, 2025 | -61.4% | 116 days | Not yet recovered |
| Nov 4, 2021 | May 18, 2022 | -52.1% | 134 days | 93 days (Sep 30, 2022) |
| Feb 8, 2021 | Mar 29, 2021 | -43.3% | 34 days | 36 days (May 19, 2021) |
| May 19, 2021 | Jul 16, 2021 | -36.9% | 40 days | 76 days (Nov 2, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.14B
- EPS, diluted (TTM)
- -$0.99
- Revenue (TTM)
- $275.6M
- 52-week range
- $28.54 – $54.85
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $72.5M | $88.6M | $130.2M | $199.6M | $272.3M |
| Gross profit | $54.3M | $63.2M | $90.6M | $150.4M | $204.4M |
| Operating income | $1.6M | $1.9M | $431,000 | $8.8M | $38.6M |
| Net income | -$18.0M | -$14.1M | -$24.4M | -$17.5M | -$5.1M |
| EPS (diluted) | -$0.69 | -$0.51 | -$0.75 | -$0.49 | -$0.14 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.3M | $66.8M | $47.8M | $63.7M | $71.6M | $89.1M | $44.2M | $70.7M |
| Net income | -$4.2M | $6.8M | -$17.8M | $5.0M | $1.0M | $6.6M | -$27.6M | -$17.3M |
| EPS (diluted) | -$0.12 | $0.19 | -$0.50 | $0.13 | $0.03 | $0.18 | -$0.74 | -$0.46 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $5.1M | $1.7M | $3.8M | -$22.2M | $43.9M |
| Capital expenditure | -$28.5M | -$7.8M | -$152.6M | -$38.7M | -$1.1M |
| Free cash flow | -$23.4M | -$6.1M | -$148.7M | -$60.9M | $42.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$10.9M | $22.7M | $64.5M | $1.1M | $467,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $83.9M
- Total assets
- $416.8M
- Total liabilities
- $402.0M
- Total debt
- $300.7M
- Net debt
- $216.9M
- Shareholders’ equity
- $15.2M
As of Jun 30, 2026 (filed Aug 10, 2026).
Short interest
- Shares sold short
- 7,488,381
- Days to cover
- 15.68
- Change vs previous report
- +10.5%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Feb 8, 2013
- 1-for-5
- Feb 24, 2012
- 1-for-8
- Sep 28, 2007
- 231-for-500